CASE STUDIES
2023-05-24
EuroPCR2023 | RainMed and SINOMED Made Their First Joint Appearance at the World Cardiovascular Conference, Bringing a New Collaborative Concept for Optimized Diagnosis and Treatment of Coronary Artery PCI
From May 16 to 19, 2023, RainMed Medical, an innovative medical device listed company from China, joined forces with its strategic partner SINOMED, a leading enterprise in the field of cardiovascular disease treatment, to showcase their original "Redefine PCI" collaborative concept at EuroPCR2023, a global academic conference for interventional cardiovascular medicine. The concept aims to provide tailored solutions for PCI procedures to optimize daily practice and bring optimized diagnostic and therapeutic solutions for coronary artery PCI.
See more
2023-05-12
The CCIF 2023 | RainMed Medical • "Medicine Progresses with Innovation" Coronary Physiology Symposium" Was Successfully Held
On April 22, 2023, RainMed Medical successfully held the "Medicine Progresses with Innovation" Coronary Physiology Symposium at the 26th China Cardiology Intervention Forum (CCIF 2023). In order to promote the diagnostic concepts of coronary physiology evaluation and the clinical application of computed coronary physiology indicators, RainMed invited well-known experts in cardiovascular field to the symposium to discuss the latest advancements in the evaluation of coronary physiology and to explore the application prospects of innovative computed coronary physiology indicators, caFFR and caIMR systems.
See more
2023-05-06
RainMed Medical Was Selected as "One of the First Demonstration Units of Trade Secret Protection in Suzhou"
RainMed Medical Was Selected as "One of the First Demonstration Units of Trade Secret Protection in Suzhou"
See more
2023-04-28
Paper Summary of RainMed's caFFR & caIMR (2)
Paper Summary of RainMed's caFFR and caIMR (2)
See more
2023-04-21
Paper Summary of RainMed's caFFR & caIMR (1)
Paper Summary of RainMed's caFFR & caIMR (1)
See more
2023-04-12
RainMed Medical Has Been Comprehensively Promoting the Business Integration of Your Health to Jointly Start a New Journey of Precision Diagnosis and Treatment
Suzhou RainMed Medical Technology Co., Ltd.(hereinafter referred to as "RainMed") has officially completed the acquisition of Tianjin Your Health Biotechnology Co., Ltd. (hereinafter referred to as "Your Health"). Recently, Yunfei Huo, Chairman of the Board of Directors, Executive Director and CEO of RainMed, Yonghui Lv, Executive Director and co-CEO of RainMed, and Zhibo He, General Manager of Your Health, have made business connections and integration on behalf of both sides. In the future, the two sides will make full use of their technological resources to develop cutting-edge in vitro diagnostic products, and jointly start a new journey of precision medicine.
See more
2023-04-07
RainMed Medical was Invited to Attend China-Uzbekistan Medical Cooperation and Development Forum to Promote Health Collaboration Between Medical Enterprises of the Two Countries
At the end of March 2023, the China-Uzbekistan Medical Cooperation and Development Forum, co-sponsored by China Chamber of Commerce for Import & Export of Medicines & Health Products and the Pharmaceutical Development Bureau of Investment, Industry and Trade of Uzbekistan, and co-hosted by China-Central Asia Health Industry Alliance and China Meheco Group Co., LTD., was successfully held in Beijing. More than 50 representatives from well-known enterprises from China and Uzbekistan attended the conference. RainMed Medical was also invited to participate. At the conference, the participating enterprises had a lively discussion on the medical and health cooperation between the two countries, making new contributions to the new development of medical industry.
See more
2023-03-24
RainMed Medical Has Donated Its Precision Diagnostic Products to Chinese Primary Health Care Foundation to Promote the Benifit of Medical Science and Technology Among the Grassroots
On March 9th, 2023, RainMed Medical donated dozens of sets of coronary angiography-derived fractional flow reserve measurement systems to Chinese Primary Health Care Foundation. Hui Wang, Deputy Secretary-General of the Foundation, and Yonghui Lv, Executive Director and co-CEO of RainMed Medical, signed the donation cooperation agreement on behalf of both sides. Professor Zheng Zhang from Beijing well-known Class A hospital attended and witnessed the signing ceremony. This donation will help bring high-quality medical resources to the grassroots, promote the development of coronary artery precision diagnosis and treatment, and implement the hierarchical diagnosis and treatment system.
See more
2023-03-17
Suzhou RainMed Medical Technology Co., Ltd. Will Acquire a 68.32% Stake in Tianjin Your Health Biotechnology Co., Ltd. to Extend Its Precision Diagnostic Product Pipeline
RainMed Medical-B (02297.HK) announced that on March 1st, 2023, Suzhou RainMed Medical Technology Co., Ltd. (hereinafter referred to as "RainMed") will acquire a 68.32% stake in Tianjin Your Health Biotechnology Co., Ltd. (hereinafter referred to as "Your Health") at a total cost of RMB 25.96 million. This strategic merger and acquisition has extended RainMed’s precision diagnosis product pipeline from "covering the whole procedure of PCI" to "inspection on admission" and "inspection at the bedside", providing new momentum for its long-term development.
See more
2023-03-10
LATEST! RainMed's caFFR System Has Been Commercialized in Serbia, Accelerating the Overall Process of Overseas Commercialization
In February 2023, RainMed's caFFR was commercially launched in the Republic of Serbia and successfully completed its first charging case in Serbia’s national institute of cardiovascular diseases, KBC Dr Dragisa Misovic-Dedinje.
See more
2023-03-03
RainMed Medical and SINOMED Signed a Strategic Collaboration Agreement to Jointly Promote the Development of Precision Medicine
On February 28, 2023, RainMed Medical (stock code: 2297.HK) and SINOMED (stock code: 688108.SH) held a strategic collaboration agreement signing ceremony in Beijing. Mr. Yunfei Huo, chairman of the board, executive director and CEO of RainMed Medical, and Mr. Jianhua Sun, chairman and CEO of SINOMED, signed the agreement on behalf of both parties. Professor Yong Huo from Peking University First Hospital, and Professor Yunlong Huo, Co-founding shareholder of RainMed Medical and professor of School of Life Science and Biotechnology of Shanghai Jiao Tong University, also attended the meeting.
See more
2023-02-24
RainMed Medical is Applying for MDSAP to Accelerate Its Layout of International Marketing System
Recently, RainMed Medical is applying for MDSAP (Medical Device Single Audit Program). It is expected that the MDSAP certification issued by international authoritative certification body will further lay the foundation for RainMed's global development strategy.
See more
2023-02-17
RainMed Medical was Delighted to Welcome Qiao Zhang, Deputy Mayor of Suzhou, to Investigate and Support the Independent Innovation and Development of Domestic Medical Technology
Recently, Qiao Zhang, deputy mayor of Suzhou Government, deputy chairman of Jiangsu Committee of Chinese Peasants’ and Workers’ Democratic Party，chairman of Suzhou Committee of Chinese Peasants’ and Workers’ Democratic Party, made a field investigation of RainMed. He had a discussion on the independent innovation of domestic medical devices with Yunfei Huo, chairman of the board of directors, executive director and CEO of RainMed Medical. Kangjian Liu, vice president and secretary of the board of directors of RainMed, introduced RainMed's development strategy and core products. Yang Gu, vice president of RainMed and Chang Zhou accompanied them during the investigation. Hong Sun, deputy director of Suzhou Bureau of Industry and Information Technology; Jianhong Zhang, secondary researcher and full-time deputy chairwoman of Suzhou Committee of Chinese Peasants’ and Workers’ Democratic Party; Hongmei Lin, deputy minister of Suzhou Industrial Park Publicity and United Front Work Department and director of the Municipal Bureau of Ethnic and Religious Affairs participated in the investigation and exchange activity.
See more
2023-02-09
Successfully Concluded! RainMed Made a Stunning Appearance at High Tech Cardio 2023 Exhibition with Its Star Product caFFR
From February 1st to 3rd, 2023, the offline exhibition of High Tech Cardio Conference was grandly held at Palais du Pharo in Marseille, France. As one of the most prestigious exhibitions in Europe for sharing and exchanging cutting-edge technology and clinical treatment research of interventional cardiology, the exhibition has attracted many high-tech medical device companies and top European experts from all over the world. Exhibitors included medical device giants such as Abbott, Boston Scientific, Edwards LifeSciences, Medtronic and Philips. As a Chinese innovative company, RainMed was invited, showing the unique technical charm of its product caFFR.
See more
2023-02-03
Strong Alliance! RainMed will Be Collaborating with Corrib Core Lab in Ireland to Carry Out a Coronary Clinical Trial
RainMed, an innovative medical device company from China, will collaborate with CORRIB Research Centre for Advanced Imaging and Core laboratory at University of Galway, Ireland, to carry out a coronary clinical trial. In the clinical trial, researchers will test caFFR, a coronary angiography-derived fractional flow reserve measurement system.
See more
2023-01-13
In 2022, RainMed Deepened Its Clinical Cooperation, Pushing the Development of Coronary Physiology to a New Level
A summary of RainMed in 2022.
See more
2023-01-06
High Tech 2023丨RainMed's caFFR will be present at French Congress of Cardiovascular Diseases
RainMed’s caFFR will be exhibited at the offline exhibition of High Tech Cardio in Palais du Pharo, Marseille, France From February 1st to 3rd , 2023. High Tech is a professional congress gathering top interventional cardiology experts from France and the European Society of Cardiology to share cutting-edge technologies and clinical treatment research of interventional cardiology. It attracts top European experts and scholars, as well as major medical device enterprises on interventional cardiology treatment every year.
See more
2022-12-30
The First Chinese Expert Consensus on Clinical Pathways of Coronary Artery Computational Physiology Detection Indicators was Officially Released, Promoting the Development of Coronary Function Evaluation to a New Level!
Recently, led by Academician Junbo Ge from Fudan University Zhongshan Hospital, Professor Yong Huo from Peking University First Hospital and supported by domestic independent innovation enterprise RainMed Medical, Chinese Expert Consensus on Clinical Pathways of Coronary Artery Computational Physiology Detection Indicators (hereinafter referred to as "Consensus") was officially released on the bank of Huangpu River. It took more than 7 months from the drafting to the release, innovatively included RainMed’s caFFR and caIMR into studies, and made detailed descriptions of their operating norms and application scopes, which provides practical guidelines for clinical use of coronary function evaluation, and creates an open market space for RainMed Medical’s coronary functional series products.
See more
2022-12-23
RainMed Won a Series of Industry Awards, Creating a New Situation for Precision Medicine in Interventional Cardiology
Recently, Suzhou RainMed Medical Technology Co., Ltd. frequently obtained the recognition of industry authority , showing its excellent comprehensive strength and leading advantage in research and development level and innovation as well as business layout.
See more
2022-12-16
New Progress Has Been Made in the Clinical Study of RainMed’s caIMR System: It Can Independently Predict the Prognostic Value of Overweight Patients with Chronic Coronary Syndrome , and Improve the Global Epidemic Management Level
Recently, a team from Tenth People’s Hospital of Tongji University published a clinical research paper -- "Prognostic impact of coronary microvascular dysfunction assessed by caIMR in overweight with chronic coronary syndrome patients" in an internationally renowned SCI journal. It is a groundbreaking study on the impact of coronary microvascular dysfunction in patients with overweight and chronic coronary syndrome (CCS). Results show that as the world's first non-interventional microcirculatory function diagnostic product, RainMed’s caIMR is an independent predictor of MACE in overweight patients with CCS which offers objective risk stratification for obese patients. This conclusion broadens the clinical application scenario of caIMR system, helps promote the process of epidemic management in China, and creates a new opportunity for large-scale clinical application of caIMR.
See more
2022-12-09
RainMed Medical was Nominated for the 4th Chip Award for Its Innovation in Medical Device!
Recently, the 11-month fourth "Chip Award" of China Health Care Innovation Platform 2022 was officially held in Shanghai. After rigorous screening by more than 80 authoritative experts, RainMed Medical passed the test and stood out in nearly 300 innovative projects. Together with Innovent, RemeGen, Hutchison Pharmaceuticals and other leading enterprises in the industry, RainMed Medical won the "Medical Device Innovation Chip Award Nomination Award". This award highlights the superb product innovation ability and marketing of RainMed Medical, which is highly competitive in the industry.
See more
2022-12-02
The 17th Zunyi Cardiovascular Conference | RainMed Medical· Forum on Coronary Function was Successfully Held
On November 19th, 2022, RainMed Medical successfully held a forum on coronary function in the 17th academic conference on Cardiovascular Disease Diagnosis and Treatment Guidelines and Standardized Diagnosis and Treatment Training (Zunyi Cardiovascular Conference)-- Coronary Innovation Forum. In order to popularize the concept of functional diagnosis and promote the clinical application of the calculation of coronary physiological indicators, the forum invited famous experts in the field of cardiovascular disease in China, introduced the latest progress of coronary function, shared the clinical application of innovative computational coronary physiological indicators caFFR and caIMR, and imparted the application skills.
See more
2022-11-18
The First Clinical Study Results of RainMed's caFFR at Heart Centre in Southeast Asia were published! caFFR-guided Deferral of PCI was Safe and Comparable to Wired-based FFR Guidance!
Recently, Dr. Chandan Deepak Bhavnani from Pusat Jantung Sarawak and president of National Heart Association of Malaysia Dr. Alan Yean Yip Dr Fong's team published results of a clinical trial using coronary angiography-derived fractional flow reserve measurement system caFFR. The paper was published in Journal of Asian Pacific Society of Cardiology (JAPSC). This was the first study of its kind in Southeast Asia. Based on previous trials, this trial advances the clinical significance of caFFR value for intermediate coronary artery stenosis. The results showed that caFFR had a good agreement with wire-based FFR. The 12-month outcomes showed that caFFR-guided deferral of PCI was safe and comparable to wired-based FFR guidance.
See more
2022-11-11
RainMed Actively Responds to Financial Discount Interest Policy! Its Integrated Diagnosis and Treatment Plan of Vascular Diseases Promotes the Homogenization of the Diagnosis and Treatment Level Among Regions
Recently, there is a bunch of good news in the field of medical device. A few days ago, the State Council executive meeting decided to use special re-loans and financial discount interest to support the renovation of equipment in some areas, increase market demand, and increase the development momentum. At the same time, the National Health Commission also issued a notice of upgrading medical device with financial discount loans. This policy will surely stimulate the vitality of hospital procurement and promote domestic innovative medical devices to grow with vigorous market vitality
See more
2022-11-04
GW-ICC 2022 | RainMed Medical Successfully Held a Satellite Symposium on Computational Coronary Physiology
On October 29th, 2022, during the 33rd Great Wall International Congress of Cardiology, Asia Heart Society Congress 2022, in order to popularize the concept of coronary functional evaluation and promote the clinical application of computational coronary physiological indicators, RainMed Medical successfully held a satellite symposium of computational coronary physiology. The well-known experts in the field of cardiovascular were invited, and they discussed and prospected the latest progress of coronary functional evaluation technology, and shared the clinical experience of innovative computational physiology indicators caFFR and caIMR. It is worth noting that it is the first time that RainMed shared clinical cases of caIMR in satellite symposiums in such a national academic congress, which has attracted widespread attention and aroused heated discussion among participants.
See more
2022-10-28
Exhibition is Underway! RainMed's caFFR Unveiled for the First Time at the 18th Malaysian Cardiovascular Intervention Symposium
RainMed's caFFR Unveiled for the First Time at the 18th Malaysian Cardiovascular Intervention Symposium
See more
2022-10-21
The Vice Minister Wenpu Ma and Academician Yan Shen Visited RainMed Medical for Inspection and Guide the Development of Domestic Innovative Medical Devices
Recently, Mr. Wenpu Ma, former vice minister of the International Department of Central Committee of CPC, Former Vice Director of the 11th NPC Foreign Affairs Committee, and Professor Yan Shen, former vice chairman of China Association for Science and Technology (CAST), former deputy of National Natural Science Foundation of China and member of Chinese Academy of Sciences and the other two people visited Beijing office of RainMed Medical and fully affirmed the achievements of RainMed Medical in scientific and technological innovation. Mr. Kangjian Liu, Vice President and Secretary of the Board of Directors of RainMed and Mr. Liang Wan, Director of Government Affairs Department, accompanied them during the visit.
See more
2022-10-14
Good News! RainMed's caFFR System Has Been Successfully Certified by Australian TGA, Unlocking a New Area in Overseas Market!
On September 29th, 2022, RainMed Medical Co., LTD. (Stock Code: 2297.HK, hereinafter referred to as "RainMed") officially announced that its caFFR system has been successfully approved by Australian Government Department of Health Therapeutic Goods Administration(TGA), unlocking a new area in overseas market. Having got TGA’s recognition means RainMed has taken a solid step in accelerating its layout of international marketing system!
See more
2022-09-30
TCT 2022丨RainMed caIMR Presented at the Transcatheter Cardiovascular Therapeutics Conference, Providing a New Solution for Global Coronary Microcirculation Function Assessment
RainMed Medical, an innovative medical device enterprise from China, was invited to deliver a speech at TCT to announce its latest clinical trial data because of the original breakthrough technology of caIMR in coronary microcirculation function assessment, which showed the world China's local innovation strength.
See more
2022-09-23
2022 China Medical Device Outbound Conference | RainMed’s caIMR Series Won the Award of "2022 Most Innovative Outbound Medical Devices", Which Will Further Demonstrate the Infinite Charm of China’s Smart Manufacturing on the Global Stage
In September 2022, RainMed Medical was invited to participate in the 2022 China Medical Device Outbound Conference hosted by the International Health Exchange and Cooperation Center NHC PRC (IHECC) and VBDATA.CN.
See more
2022-09-08
2022CHC·Surgical Robot Forum: RainMed Medical Announced to Build Its Own Vascular Interventional Surgery Robot to Promote the Realization of Unmanned Operating Room
On September 1st, 2022, the "2022CHC·Citic Securities Healthcare Conference and the 11th China MedTec CEO Summit" jointly hosted by CHC Healthcare Consulting and Citic Securities, was held in Hefei, Anhui Province. The conference focused on cutting-edge research and held a special forum on surgical robots. As the strategic partner of the conference and the leader of the vascular interventional surgery robot field, RainMed Medical was invited to attend the forum. Mr. Kangjian Liu, Vice president and Secretary of the Board announced that RainMed Medical will build a platform-level vascular interventional surgery robot to promote the realization of an unmanned operating room with automated diagnosis and treatment.
See more
2022-09-02
RainMed Medical Satellite Symposium Has been Successfully Held During the 21st Cardiovascular Disease Academic Conference of Shanxi Medical Association
On August 27, 2022, during the 21st Cardiovascular Disease Academic Conference of Shanxi Medical Association, RainMed Medical successfully held a satellite symposium in order to popularize the clinical application of calculating coronary physiological indicators and promote precise interventional treatment of coronary heart disease. Renowned experts in the field of cardiovascular diseases were invited to discuss the latest progress of coronary functional evaluation technology and the clinical application of innovative functional indicators caFFR and caIMR.
See more
2022-08-26
The Kick-off Meeting of "Expert Consensus on Clinical Pathways of Coronary Artery Computational Physiology Testing Indicators in China" Led by Academician Junbo Ge and Supported by RainMed Medical Was Held in Anhui Province
On August 20, 2022, during the fourth Confucianism and Taoism International Congress of Cardiology (CTCC), the kick-off meeting of "Expert Consensus on Clinical Pathways of Coronary Artery Computational Physiology Testing Indicators in China", led by Academician Junbo Ge from Fudan University Zhongshan Hospital and supported by RainMed Medical, was held in Anhui province.
See more
2022-08-19
Strategic Cooperation | RainMed Medical and Angiotec Signed a Strategic Cooperation Agreement to Accelerate the Development of Integrated Solutions for Cardiovascular Operating Rooms
On August 16, 2022, RainMed Medical Co., LTD. (hereinafter referred to as "RainMed", stock code: 2297.HK) and Angiotec （Tianjin）Technology Co., Ltd. (hereinafter referred to as "Angiotec”) held a signing ceremony for strategic cooperation in Tianjin. Mr. Yunfei Huo, Chairman of the Board, Executive Director and Chief Executive Officer of RainMed and Mr. Da Zhuo, General Manager of Angiotec signed the agreement on behalf of both companies. Mr. Yonghui Lv, Executive Director and co-Chief Executive Officer of RainMed also attended the meeting.
See more
2022-08-12
Initial Release of caIMR's Clinical Application Potential! RainMed’s caIMR Empowered the development of clinical treatment strategies, adding strong evidence for the concept of "intervention without implantation" for STEMI patients
Recently, Professor Zhirong Wang's team from The Affiliated Hospital of Xuzhou Medical University published a paper in SCI journal titled "Computational Pressure-Fluid Dynamics Applied to Index of Microcirculatory Resistance, Predicting the Prognosis of Drug-Coated Balloons Compared With Drug-Coated Balloons Compared With Drug-Eluting Stents in STEMI Patients". The paper indicates that RainMed’s caIMR can independently predict the likelihood of cardiac death or readmission due to heart failure in STEMI patients. At the same time, caIMR confirmed that the effect of drug-coated balloon (DCB) therapy is not inferior to drug-eluting stent (DES) in the diagnosis and treatment of STEMI by accurately diagnosing the damage of coronary microcirculation. It has added strong clinical evidence for the advanced diagnosis and treatment concept of "intervention without implantation" in STEMI patients and assisted clinical development of better interventional diagnosis and treatment strategy.
See more
2022-07-29
18th YRICC | RainMed Medical Satellite Symposium Has Been Successfully Held
On July 22nd, 2022, during the 18th Yellow River International Cardiology Conference (YRICC 2022), RainMed Medical successfully held a satellite symposium. Renowned cardiovascular experts from all over the country had a heated discussion on research progress, clinical significance and application scenarios of caFFR and caIMR.
See more
2022-07-15
Warmly Celebrate the Successful Listing of RainMed on the Hong Kong Stock Exchange
On July 8, 2022, Suzhou RainMed Medical Technology Co., LTD. (02297.HK, hereinafter referred to as "RainMed Medical") was officially listed on the main board of Hong Kong Stock Exchange and held a bell ringing ceremony at 9:30 am.
See more
2022-07-08
ICC 2022 | RainMed Medical Successfully Held the Physiological Function Forum
On July 3rd, 2022, during the 17th Ice City Conference of Cardiology (ICC 2022), RainMed Medical successfully held the Physiological Function Forum. Renowned cardiovascular experts from all over the country had a heated discussion on research progress, clinical significance and application scenarios of caFFR and caIMR.
See more
2022-07-01
RainMed Medical Entered "TOP100 MEDICAL DEVICE COMPANIES"
In the sixth 2022 Future Healthcare VB100 Conference, RainMed Medical was identified as one of the "TOP100 Medical Device Companies” in China. This list is the most concerned annual list launched by VBDATA.CN and VCBeat Research (VBR) in the field of life and health among industry and capital circles. Meanwhile, it is also the first innovative medical list of unlisted enterprises in China. RainMed Medical has brought new solutions to world's problems with China's local innovation.
See more
2022-06-24
FIVE Amazing Features of caIMR | RainMed's Satellite Symposium at CIT was Successfully Held
At present, there is no clinical quantitative measurement product that can easily and effectively diagnose coronary microcirculation. The large-scale clinical application of caIMR--the global pioneering technology--will surely bring epoch-making significance to precise diagnosis and treatment in cardiovascular field, and provide diagnostic basis and research direction for the development of microcirculation drugs and devices. To conclude, why is caIMR so promising? We can refer to the following five reasons.
See more
2022-06-17
OCC 2022 | Chairman of OCC Announced the Results of Flash III Clinical Research, Confirming that caIMR Has High Diagnostic Accuracy
Recently, the 16th Oriental Congress of Cardiology was grandly held. Meanwhile, RainMed’s Satellite Meeting was also held at noon. During the conference, Junbo Ge, president of OCC Conference, chief of cardiology department of Zhongshan Hospital, Fudan University and academician of Chinese Academy of Sciences announced the results of Flash III trial. Compared with guidewire-based IMR, the online measurement accuracy of caIMR is up to 93.81%, and the offline accuracy is up to 94.69%. This exciting research result has aroused enormous experts and scholars' attention and heated discussion. In addition, the role of functional evaluation was discussed in the research progress of diagnosis and treatment of coronary heart disease and the coronary microvascular disease. Cases guided by caFFR and caIMR were shared.
See more
2022-06-10
New Progress! RainMed's Transducer Compatible with both caFFR and caIMR Got a New English Name
On June 7th, 2022, RainMed's transducer compatible with both caFFR and caIMR got a new English name after voting—CadiFlash, which means RainMed has made a new progress in the internationalization of caFFR and caIMR.
See more
2022-05-27
New Era of Precision Medicine! EuroPCR Announced Exciting Results of caIMR’s Clinical Experiments on the Coronary Microcirculation Diagnosis
Recently, at EuroPCR2022, the official annual meeting of the World-Leading Course in Interventional Cardiovascular Medicine and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), chief of cardiology department of Zhongshan Hospital, Fudan University and academician of Chinese Academy of Sciences Junbo Ge announced the excellent results of the clinical trial of Flash III supported by RainMed Medical. Data shows that compared with wire-based IMR, caIMR has high accuracy, sensitivity and specificity. This means that large-scale clinical application of caIMR will surely improve the level of diagnosis and treatment of coronary artery disease and lead precision medicine into a new era.
See more
2022-01-21
RainMed Medical builds a high-end circle of friends in the field of accurate diagnosis and treatment
At present, RainMed Medical has successively established strategic cooperative relations with top enterprises such as Ping An Capital, GE Medical China, China Resources Medical Devices, Jointown Medical Devices, Hanxiputai and so on. Through a series of strategic cooperation, RainMed Medical builds a high-end circle of friends in the field of accurate diagnosis and treatment, jointly promotes the capital operation, technology innovation, marketing, channel building, and accelerates the ecological building and strategic implementation of vascular interventional surgery robots to better empower clinicians and benefit the patients with cardiovascular disease at home and abroad.
See more
2022-01-12
RainMed set off a new upsurge of clinical research
In recent years, RainMed Medical has continued to establish close scientific research cooperation with dozens of domestic and foreign top medical centers, such as Zhongshan Hospital affiliated to Fudan University, Peking University First Hospital, Peking Hospital, Sungkyunkwan University Samsung Medical Center in South Korea, and continue to publish more than 20 articles in famous SCI journals. Four of the articles were included in top journals such as and , leading the upsurge of clinical research on coronary function.
See more
2022-01-07
During the China Cardiovascular Health Conference 2021, RainMed Coronary Physiology Forum was successfully held
On December 18th, 2021, RainMed Coronary Physiology Forum was successfully held during the China Cardiovascular Health Conference 2021. Renowned cardiovascular experts from all over the country held a heated discussion on the research progress, clinical significance and application scenarios of caFFR and caIMR, angiography-derived coronary function assessment indicators.
See more
2021-12-20
RainMed products have obtained the national sales license issued by the local medical device regulatory authority in Serbia
On October 21st, 2021, Suzhou RainMed Medical Technology Co., Ltd. (hereinafter referred to as "RainMed") announced that its products Coronary Analysis System caFFR (model ASC15) and Disposable Blood Pressure Transducer (model CPT-1500) have obtained the national sales license issued by the local medical device regulatory authority in Serbia, which marks the launch of caFFR in Serbia.
See more
Previous page
1
Next page
CONTACT US
0512-62622215
Address: Building 31, Northeast District, Nano City, No. 99 Jinji Lake Avenue, Suzhou industrial park
E-mail: market@rainmed.com
WeChat public account
Recruitment QR Code
Page Copyright© 2021- Suzhou Rainmed Medical Technology Co., Ltd. 苏公网安备32059002003601号 (苏)-非经营性-2021-0149
